SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending due to positive trial results for its PoNS device in stroke rehabilitation, sparking community excitement about its potential FDA submission under Breakthrough Device Designation. The community is actively discussing the low float and potential for a short squeeze, while some caution about potential dilution. Broader context includes the company's focus on neuromodulation therapies and its existing FDA approval for multiple sclerosis.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its dedicated community and consistent growth over the past nine months, setting new all-time highs. The community is energized by a current buy contest and anticipates increased exposure with an upcoming listing, as well as an airdrop. Many believe $BROKE.X is undervalued and poised for a significant breakout, emphasizing its resilience and potential in the altcoin space.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia ($NVDA) is trending amid news of China investigating potential antitrust violations related to a past acquisition, sparking concerns about market access and potential penalties. The community debates the significance of this development, with some viewing it as an opportunity to buy the dip while others express concerns about the stock's vulnerability to negative China-related headlines and potential broader market impacts. Despite the uncertainty, some remain optimistic about Nvidia's long-term prospects, citing its leadership in AI and strong fundamentals.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma is trending as traders anticipate the release of Phase 3 trial data for their lead drug, Efzofitimod, with potential implications for treating pulmonary sarcoidosis; the community is discussing possible outcomes and speculating on a short squeeze, while acknowledging the inherent risks of a binary biotech event; some are closely watching for early data leaks or unusual trading patterns, while others are reviewing past trial data and KOL opinions to inform their investment decisions.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors discuss its high short interest and potential for a squeeze, with some citing the upcoming Rumble Wallet launch and the Northern Data acquisition as possible catalysts. JD Vance's exclusive on the platform and overall ties to prominent figures are also fueling community speculation. Despite some frustration with the stock's performance, bulls remain optimistic about its long-term potential, particularly with its connections to crypto and a shift towards alternative media.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to its recent merger with Strive and a strategic shift towards Bitcoin, sparking discussions of a potential short squeeze. The community is focused on high short interest, borrow fees, and the possibility of forced buy-ins, with many anticipating significant price movement. Some traders are experiencing trading restrictions, while others speculate on the impact of potential dilution from warrants.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending amid excitement surrounding upcoming presentations at the Quantum World Congress and UK regulatory approval for its acquisition of Oxford Ionics. The community is actively debating whether IONQ can achieve a market capitalization similar to that of NVDA, and many are citing the stock's potential for significant long-term gains while some discuss short-term profit taking.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending amid rising Q3 delivery expectations and increased energy storage discussion. Community chatter highlights Barclays raising delivery expectations, robotics potential, and the cult-like following the stock commands. Some caution remains due to ending tax credits and potential bank target revisions.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending due to positive sentiment around nuclear energy deals and potential entry into the US SMR market. Community members are discussing the UK's commitment to nuclear expansion and anticipating further news from upcoming industry events. Increased defense spending and potential partnerships related to AI data centers are also driving interest in the stock.

BlackRock Institutional Trust Company N.A. - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is trending due to a mix of factors, including reactions to Nvidia's potential to resume AI chip sales in China and overall optimism in the semiconductor sector. Community discussions revolve around SOXX's technical indicators, potential pullbacks, and strategies involving leveraged ETFs like SOXL and SOXS. Broader market context includes the AI boom, geopolitical tensions, and upcoming earnings reports from major semiconductor companies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

In the latest trading session, Gilead Sciences (GILD) closed at $117.86, marking a +2.26% move from the previous day.

U.S. stocks closed Wednesday’s session mixed, with the broader S&amp;P 500 Index and the Nasdaq Composite hitting fresh highs, while the Dow Jones Industrial Average retreated.Although the tame producer price inflation report generated some strength in the market in the morning session, the perils of trading an overbought market made traders cautious as the session progressed.The following stocks saw the biggest volume surge in extended trading, even as the market turns its attention to the August consumer price inflation CPI) report due on Thursday:SLB Ltd. (SLB)After-hours move: 0.14%Trading volume: 5.86 millionOilfield services company SLB remained on investors’ radar despite the lack of any significant news. The Houston, Texas-based company’s shares rose over 1% on Wednesday, outperforming the broader market, after crude oil futures climbed 1.7% during the session.&nbsp;The stock, however, is down 3.5% for the year-to-date period.<figure class="image"><img style="aspect-ratio:618/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_40_24_AM_png_ff671b9818.webp" alt="Screenshot 2025-09-11 at 12.40.24 AM.png" width="618" height="54"><figcaption>SLB sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/SLB">SLB stock</a> remained ‘neutral’ (51/100) by late Wednesday, and the message volume also stayed ‘normal.’Apple, Inc. (APPL)After-hours move: +0.10%Trading volume: 4.67 millionApple’s stock tumbled over 3% on Wednesday, even as the broader market managed to close in the green. The drop came despite the stock snagging a slew of price target hikes from Wall Street firms following the “Awe Dropping” hardware launch event held on Tuesday.BofA, Rosenblatt, Melius Research and Evercore ISI were among the firms that upped their price targets for Apple’s stock, with the updated estimates from these firms ranging from $241 to $290, the Fly reported. JPMorgan and Citi said the launch event was aligned with their expectations, while Morgan Stanley said it was slightly more awe-dropping than expectations.<a href="https://stocktwits.com/symbol/AAPL">Apple stock</a> is down about 9.1% year-to-date (YTD).<figure class="image"><img style="aspect-ratio:615/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_42_11_AM_png_38eba34d1f.webp" alt="Screenshot 2025-09-11 at 12.42.11 AM.png" width="615" height="58"><figcaption>AAPL sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>Retail sentiment toward the stock remained ‘extremely bullish’ (85/100), and the message volume was ‘extremely high.’&nbsp;Nvidia Corp. (NVDA)After-hours move: -0.10%Trading volume: 4.21 millionNvidia rode on the back of Oracle's (ORCL) exuberance and ended Wednesday’s session up nearly 5% at $177.33, although it was off its all-time intraday high of $184.48. However, retail interest is on the wane. On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/NVDA">Nvidia stock</a> remained ‘bearish’ (37/100). The message volume on the stream was ‘low’ relative to historical norms.<figure class="image"><img style="aspect-ratio:622/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_43_57_AM_png_ec461b54d9.webp" alt="Screenshot 2025-09-11 at 12.43.57 AM.png" width="622" height="59"><figcaption>NVDA sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>The shares of the artificial intelligence chipmaker are up more than 32% this year.Merck &amp; Co. (MRK)After-hours move: +0.10%Trading volume: 3.91 millionPharma giant Merck has come onto investors’ radar as it declined on Wednesday, aligning with the pullback in the healthcare stocks in the afternoon. The S&amp;P 500 Healthcare Index fell 0.91% on Wednesday.The company also abandoned plans to build a research center in the U.K., citing the “challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments,” the London Times&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thetimes.com/business-money/companies/article/merck-attacks-uk-life-sciences-investment-scraps-1bn-hq-jbzz9nmnb">reported.</a><figure class="image"><img style="aspect-ratio:620/50;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_45_04_AM_png_6aeae81193.webp" alt="Screenshot 2025-09-11 at 12.45.04 AM.png" width="620" height="50"><figcaption>MRK sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/MRK">Merck stock</a>, which has fallen nearly 14% this year, elicited ‘bearish’ sentiment (42/100) from among users on Stocktwits. The message volume was at ‘normal’ levels.Gilead Sciences, Inc. (GILD)After-hours move: +0.65%Trading volume: 3.57 millionGildead Sciences was in the news on Wednesday as RBC Capital Markets named the company as one of the beneficiaries of Health and Human Services (HHS) Secretary and prominent antivaxxer Robert Kennedy's potential departure from the agency.&nbsp;The firm said healthcare could be viewed as "less unpredictable" and "more investable" if the secretary were to depart his position, according to the Fly.Kennedy has been under pressure from HHS employees, both former and current, to quit, as they alleged that he has put the health of America at risk with his actions, which include cancelling emergency use authorizations for COVID-19 vaccines without providing data or methods to justify the decision.<figure class="image"><img style="aspect-ratio:616/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_46_18_AM_png_9b7d1d480e.webp" alt="Screenshot 2025-09-11 at 12.46.18 AM.png" width="616" height="53"><figcaption>GILD sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/GILD">Gilead Sciences stock</a> remained ‘neutral’ (47/100). and the message volume also stayed at ‘normal’ levels.The stock has gained 26.5% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-ceo-sees-25-bps-fed-rate-cut-as-done-deal/chwN5NiRdH4">Will Fed Cut Rates Next Week? What Goldman Sachs CEO David Solomon Predicts For September Meeting And Rest Of 2025</a>

Traders work on the floor of the New York Stock Exchange (NYSE) on July 30, 2025, in New York City. 

SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?

Two stocks, each from the tech and healthcare sectors, experienced brisk trading activity in the post-market session on Wednesday, although volumes were relatively muted.

Equity

Two stocks, each from the tech and healthcare sectors, experienced brisk trading activity in the post-market session on Wednesday, although volumes were relatively muted.


Novo Nordisk shares&nbsp;climbed 0.6% in&nbsp;early premarket trading on Wednesday after the world’s most valuable drugmaker announced plans to cut 9,000 jobs and forecast billions in annual savings, even as it lowered its profit outlook for the third time this year.The Danish firm behind blockbuster obesity drug Wegovy and diabetes treatment Ozempic said it would cut 9,000 positions, or about 11.5% of its 78,400-strong global workforce, as part of a company-wide transformation. About 5,000 roles will be eliminated in Denmark.The restructuring is expected to save 8 billion Danish crowns ($1.26 billion) annually by 2026 and will focus resources on diabetes and obesity, Novo’s key growth areas.&nbsp;“Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven. Our company must evolve as well,” newly appointed Chief Executive Officer Mike Doustdar said in a statement.The overhaul is accompanied by one-off restructuring costs of 9 billion crowns in the third quarter, including impairment charges, which are partially offset by savings of 1 billion crowns in the fourth quarter.&nbsp;Novo now expects operating profit growth of 4%–10% this year at constant exchange rates, down from 10–16% forecast in August and as high as 27% projected in February.“Sometimes the hardest decisions are the right ones for the future we’re building,” Doustdar&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7371410309493846016/">said in a LinkedIn post</a>. “This is the right thing to do for the long-term success of Novo Nordisk.”Novo has already frozen hiring for non-critical roles and withdrawn offers to some new hires.&nbsp;The shake-up follows a sharp slowdown in growth, with the company losing market share in the U.S. obesity market to Eli Lilly and facing pressure from compounding pharmacies that are allowed to make copycat versions of Wegovy due to supply shortages.The company, valued at about $650 billion at its peak last year, saw $70 billion wiped off its market capitalization in July after a profit warning and the appointment of Doustdar as CEO.Novo said it will report its nine-month results and provide a fresh outlook for 2025 on Nov. 5.On Stocktwits, retail sentiment for Novo Nordisk was ‘bearish’&nbsp;heading into Wednesday’s market open.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s stock</a> has declined nearly 36% so far in 2025.($1=6.38 Danish krone)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Why Is Novo Nordisk’s Stock Rising Premarket Today?

The Danish drugmaker said an overhaul will save 8 billion crowns annually by 2026, but one-off restructuring costs will drag 2025 operating profit growth down to 4–10% from as much as 27% previously projected.

Shares of Xilio Therapeutics ended nearly 8% higher on Tuesday after the company reported positive early trial results for its cancer drug XTX301, began dosing patients in Phase 2, and secured a $17.5 million milestone payment from Gilead Sciences.Xilio said Phase 1 data for XTX301, a tumor-activated IL-12 therapy, showed anti-tumor activity in patients with advanced solid tumors, including two partial responses, while most side effects were mild or moderate.&nbsp;The treatment also sustained interferon gamma signaling across cycles, supporting the company’s approach of reprogramming “cold” tumors into inflamed “hot” ones.Based on the findings, Xilio selected a recommended Phase 2 dose and schedule and has begun treating patients in the Phase 2 portion of its ongoing Phase 1/2 trial in the U.S, which will enroll about 40 participants.&nbsp;Enrollment in Phase 1A has been completed, and Phase 1B expansion is still underway.The milestone payment from Gilead, tied to the start of Phase 2, extends Xilio’s cash runway into the first quarter of 2027. As of June 30, the company held $121.6 million in cash and equivalents and expects to receive the Gilead payment in the fourth quarter of 2025.Under their March 2024 global license agreement, Gilead may take over development and commercialization of XTX301 after reviewing clinical data, with an option fee of $75 million.&nbsp;Xilio could receive up to $500 million in additional development, regulatory and sales milestones, plus tiered royalties ranging from high single digits to mid-teens on global net sales.On Stocktwits, retail sentiment for Xilio was ‘bullish’ amid a 2,333% surge in 24-hour message volume.One user said that the stock had “solid news” but needed more trading volume to push through the $0.80 level.<stembedurl>https://stocktwits.com/MrTicker/message/627979369</stembedurl>Another user predicted the shares would climb quickly, noting it was “super hard to get shares.”&nbsp;They highlighted that Xilio held about $140 million in cash against a roughly $38 million market cap, arguing the market had assigned little to no value to its partnerships, assets, or even its cash balance, and suggesting a reprice was likely.<stembedurl>https://stocktwits.com/SteadyTrade55/message/627979366</stembedurl><a href="https://stocktwits.com/symbol/XLO">Xilio’s stock</a> has declined 21.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Xilio’s stock has declined 21.5% so far in 2025. (Photo credit: Getty Images)

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

The company has begun dosing patients in Phase 2 of its trial for XTX301, a tumor-activated IL-12 therapy that showed two partial responses in early testing and was generally well tolerated.

U.S. stocks reversed course on Monday, although trading was characterized by volatility amid the uncertainties that continue to abound. IT and consumer discretionary gained some ground, helping to offset the weakness or sluggish performances of most other sectors.Nevertheless, the Nasdaq Composite Index hit an all-time intraday and closing high.Even as the market deals with the uncertainty around the Federal Reserve’s next rate move, the following stocks saw substantial trading volume in the after-hours:Wolfspeed, Inc. (WOLF)After-hours move: +57.73%Trading volume: 26.43 millionThe increased trading volume in&nbsp;<a href="https://stocktwits.com/symbol/WOLF">Wolfspeed stock</a> was accompanied by an after-hours jump in the shares of the company, which manufactures wide-bandgap semiconductors, focusing on silicon carbide and gallium nitride materials.Wolfspeed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-wolfspeed-stock-skyrocketed-60-in-today-s-after-hours/chw0o5yRdrH">said</a> Monday after the market close that the company has received Court approval of its Plan of Reorganization, and it is slated to file a Chapter 11 bankruptcy protection&nbsp;claim over the next several weeks.Retail users of Stocktwits cheered the development, with sentiment toward Wolfspeed stock improving to ‘extremely bullish’ levels (86/100) by late Monday from ‘neutral’ a day ago. The message volume on the stream picked up pace to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:619/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_18_46_AM_png_298850cc70.webp" alt="Screenshot 2025-09-09 at 2.18.46 AM.png" width="619" height="53"><figcaption>WOLF sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>Wolfspeed stock has lost over 81% year-to-date (YTD).Nvidia Corp. (NVDA)After-hours move: -0.07%Trading volume: 6.99 million<a href="https://stocktwits.com/symbol/NVDA">Nvidia’s stock</a> rose 0.77% on Monday despite an analyst’s price target cut. Citi analyst Atif Malik reduced the price target for the stock to $200 from $210 and maintained a ‘Buy’ rating, the Fly reported. The analyst attributed his tempered opinion to Broadcom’s (AVGO) comments concerning the strong growth of its artificial intelligence (AI) chips. As such, he reduced his 2026 GPU sales estimate for Nvidia by 4%.The research firm expects a $12 billion hit to Nvidia's GPU sales from Broadcom’s XPU deals.On Monday, the Jensen Huang-led company also voiced its opinion about the GAINS AI Act, which was proposed by U.S. Senators last week to regulate AI GPU shipments to adversaries. The company reiterated that the U.S. will always be its primary market but lashed out at the bill. “While it may have good intentions, this bill is just another variation of the AI Diffusion Rule and would have similar effects on American leadership and the U.S. economy,” it said.After the market closed, Nvidia filed with a 144 statement with the SEC regarding Huang’s intention to sell 75,000 shares. It also filed a Form 4, communicating the sale of 225,000 Nvidia shares last Thursday following the exercise of options.Retail sentiment toward Nvidia’s stock stayed ‘bearish’ (32/100) and the message volume was at ‘low’ levels.<figure class="image"><img style="aspect-ratio:613/52;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_17_03_AM_png_06ec1e9d12.webp" alt="Screenshot 2025-09-09 at 2.17.03 AM.png" width="613" height="52"><figcaption>NVDA sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>The stock has gained 25% year-to-date.Gilead Sciences, Inc. (GILD)After-hours move: unchangedTrading volume: 6.97 millionThe increased trader interest in&nbsp;<a href="https://stocktwits.com/symbol/GILD">Gilead stock</a> was despite the lack of any meaningful, fresh catalysts. Last Friday, the company announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir, its twice-yearly injectable HIV-1 capsid inhibitor, for the prevention of HIV as pre-exposure prophylaxis (PrEP).&nbsp;It also broke ground at the new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City, California headquarters. This is part of the company’s proposed $32 billion investment in the U.S. through 2030.On Stocktwits, retail sentiment toward Gilead stock tempered to ‘neutral’ (54/100) from ‘bullish’ a day ago. The message volume remained ‘low.’<figure class="image"><img style="aspect-ratio:619/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_21_10_AM_png_6d02c5f0f3.webp" alt="Screenshot 2025-09-09 at 2.21.10 AM.png" width="619" height="56"><figcaption>GILD sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>The shares are up over 27% YTD.SLB Ltd. (SLB)After-hours move: unchangedTrading volume: 6.59 millionOilfield services company SLB was on investors’ radar amid the ongoing volatility in oil prices.&nbsp;<a href="https://stocktwits.com/symbol/SLB">SLB stock</a>, which is down 4.5% this year, drew ‘bullish’ sentiment (59/100) from retailer users of Stocktwits, up from ‘neutral’ a day ago. The message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_20_08_AM_png_cff58953a4.webp" alt="Screenshot 2025-09-09 at 2.20.08 AM.png" width="624" height="58"><figcaption>SLB sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>Corning, Inc. (GLW)After-hours move: +0.25%Trading volume: 5.92 millionNew York-based Corning, a maker of optical fibers and cables, and hardware and equipment products, has seen its shares rise over 54% this year.&nbsp;The stock may have evinced interest ahead of Apple’s iPhone 17 launch event scheduled for Tuesday. In early August, Apple announced a new $2.5 billion commitment to produce all of the cover glass for iPhone and Apple Watch in Corning’s Harrodsburg, Kentucky, manufacturing facility.<figure class="image"><img style="aspect-ratio:622/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_22_20_AM_png_fa0c45fe3b.webp" alt="Screenshot 2025-09-09 at 2.22.20 AM.png" width="622" height="54"><figcaption>GLW sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>Retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/GLW">Corning stock</a> has remained ‘neutral’ (49/100) and the message volume stayed ‘high.’For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-warns-getting-out-of-dollar-as-it-wallows-near-7-week-low/chw0sQWRdsc">&nbsp;‘Get Out Of US Dollar Before It’s Too Late,’ Says Peter Schiff As Greenback Wallows Near 7-Week Low: Spotlight Shifts To BLS Annual Revision</a>

Wolfspeed, Nvidia, Gilead, SLB, Corning: What Sparked Heavy After-Hours Trading In These 5 Stocks?

On Monday, the tech-heavy Nasdaq Composite climbed to a new high despite the ongoing uncertainty regarding the state of the U.S. economy and the rate outlook.

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU

Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.



Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Current Price	$113.76
Prev Close	$117.05
Open	$116.68
Dividend Yield	3.33%
50-Day Moving Average	$114.01
Beta	0.44
Avg. Volume	6.25M
PE Ratio	22.79

52-Week High	$121.83
52-Week Low	$81.83
Market Capitalization	$142.13B
EPS (Annual)	$0.3825
Price to Book	7.23
Revenue Per Employee	$1.63M
Enterprise Value/EBITDA	N/A

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GILD News

GILD Gilead Sciences, Inc.